Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease (Q87655450)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

Tali Kizhner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Yaniv Azulay

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Mariana Hainrichson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Yoram Tekoah

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Gil Arvatz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Avidor Shulman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Ilya Ruderfer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

David Aviezer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Yoseph Shaaltiel

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

10 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

13 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

259-267

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

Lysosomal storage disease: revealing lysosomal function and physiology.

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

A CASE OF “ANGEIO-KERATOMA.”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Replacement Therapy for Inherited Enzyme Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Enhanced sialylation and in vivo efficacy of recombinant human α-galactosidase through in vitro glycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Enzyme replacement therapy in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Agalsidase benefits renal histology in young patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Enzyme replacement therapy improves cardiac features and severity of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Renal manifestations in Fabry disease and therapeutic options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Phenotype and genotype characterization and twin association in patients with Anderson-Fabry cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Fabry disease in children: agalsidase-beta enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

A study on serum IgE and clinical symptomatology of atopy in patients suffering from the lysosomal storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Controlled glycosylation of therapeutic antibodies in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Influence of an ER-retention signal on the N-glycosylation of recombinant human α-L-iduronidase generated in seeds of Arabidopsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

The Fabrazyme shortage--a call to action for metabolic physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Cellular and tissue localization of globotriaosylceramide in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.08.002

10.1016/J.YMGME.2014.08.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25155442%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference